Focus Antitrust - 21 November 2018
In The News
CMA closes investigation into generic pharmaceutical products
The CMA has closed one of its investigations into the generic pharmaceutical products sector. The investigation related to alleged anti-competitive agreements and/or concerted practices in this sector and has been closed on administrative priority grounds. Click here.
European Commission approves acquisition of Europac by DS Smith subject to conditions
The European Commission has approved the acquisition of Europac by DS Smith, both manufacturers of paper and packaging products. The decision is conditional on the divestment of a number of production plants in Portugal and France. Click here.
- The European Commission has approved the acquisition of Shire by Takeda Pharmaceutical Company. The decision is conditional on the divestment of a biologic treatment product under development by Shire to treat inflammatory bowel disease. Click here.
- The CMA has launched an investigation into suspected anti-competitive arrangements in the financial services sector which may infringe Chapter I of the Competition Act 1998 and/or Article 101. The CMA and the Financial Conduct Authority have concurrent functions to enforce competition law infringements in the financial services sector and it has been agreed that the CMA will exercise those functions in relation to this investigation. Click here.
For more information please contact Paul Stone on +44 (0)20 7203 5110, or at firstname.lastname@example.org.
News & Insights
Charles Russell Speechlys releases H2 2020 deal highlights
Our highlights over the past 6 months are now available.
Haliburton v Chubb: The final say on an arbitrator’s duty of disclosure
We consider some of the key points when appointed arbitrators do not agree on the appointment of the third arbitrator as chairman.